Dengue virus (DENV) is an arthropod-borne flavivirus that is endemic in tropical and subtropical regions, causing hundreds of millions of infections annually (1). It is subdivided into 4 serotypes, DENV-1–4. After infection, patients have lifelong immunity against the homologous serotype but remain susceptible to infections with the others (2). Such secondary infections have been shown to be a risk factor for severe dengue with life-threatening clinical manifestations, including dengue hemorrhagic fever or dengue shock syndrome (3). Thus, monitoring the serotype is essential for outbreak management, epidemiologic studies, and patient care. Analyses are often performed by using direct virus detection methods, such as PCR and nonstructural protein 1 (NS1) antigen capture (4). Despite the high specificities of these assays, their main disadvantages include a rather small diagnostic window for detection and, for NS1 antigen capture tests, low sensitivities during secondary DENV infections (5). Identification of the infecting serotype by serologic methods is hampered by the cross-reactivity of antibodies elicited by the immune response against flaviviruses (6). Previous reports have shown that the insertion of mutations in the conserved fusion loop domain of flavivirus envelope proteins reduces this cross-reactivity in diagnostic testing (7–9). Using this method, we developed a DENV-specific ELISA capable of differentiating DENV from other clinically relevant flaviviruses, such as Zika virus, West Nile virus, and tick-borne encephalitis virus (10). In this study, we evaluated the potential of this technique to distinguish the 4 DENV serotypes during the acute phase of infection on the basis of IgM detection.

**The Study**

We acquired DENV PCR–confirmed and, thereby, serotype-classified serum samples that we divided into 2 groups: those from returning travelers with residence in Italy or Germany (n = 45), collected from patients 5–60 days after symptom onset during 2013–2016; and those from persons residing in the DENV-endemic countries of Sri Lanka (n = 43), Vietnam (n = 24), Venezuela (n = 5), and Brazil (n = 2), collected from patients 2–8 days after symptom onset during 2013–2018. We also had a set of 14 DENV PCR–negative but NS1-positive (PLATEILA DENGUE NS1 AG; Bio-Rad, Hercules, CA, USA) serum samples from patients in Vietnam that were collected during the same outbreak as the other patients from Vietnam with DENV PCR–positive test results. Ethics approvals were obtained from the respective local authorities for all samples.

We first tested all serum samples with a DENV-specific ELISA that used 4 recombinant DENV envelope proteins (1 per serotype) containing 4 point mutations in and near the conserved fusion loop (called Equad proteins) (9). All samples were positive for DENV IgM (S. Ulbert, unpub. data). This Equad-based ELISA was previously shown to be capable of discriminating DENV from other flaviviruses (9,10). We took the Equad antigens from this ELISA and created a DENV serotyping ELISA. In brief, we titrated serum samples (1:100–1:12,800 in serial 2-fold dilutions) in duplicate on plates coated with DENV-1–4 Equad proteins (Appendix, https://wwwnc.cdc.gov/EID/article/25/1/18-0605-App1.pdf) (10). We defined the endpoint titer for every serotype as the last dilution presenting
a signal above the cutoff (Appendix Table), which was calculated as the mean plus 2 times the SD of 15 flavivirus-negative control serum samples (diluted 1:100) acquired from Padova University Hospital, Padova, Italy.

Results showed 1 dominant serotype (Figure 1) for 91.1% of serum samples from returning travelers and 86.5% of serum samples from residents of DENV-endemic countries (Appendix Figures 1, 2). Compared

**Table 1. Dominant serotype determined by DENV serotype–specific IgM ELISA and ELISA specificity, by cohort and serotype, 2013–2018***

| Cohort, DENV serotype† | No. samples | Dominant serotype, no. (%) samples | Serotype specificity‡ |
|------------------------|-------------|-----------------------------------|-----------------------|
|                        |             | No. (%)                             | No. samples | % Samples (95% CI) |
| Returning travelers    |             |                                    |            |                   |
| DENV-1                 | 16          | 14 (87.50)                          | 14         | 87.50 (61.65–98.45) |
| DENV-2                 | 11          | 10 (90.91)                          | 8          | 72.73 (39.03–93.98) |
| DENV-3                 | 10          | 9 (90)                              | 9          | 90.00 (55.50–99.75) |
| DENV-4                 | 8           | 8 (100.00)                          | 7          | 87.50 (47.35–99.68) |
| All serotypes          | 45          | 41 (91.11)                          | 38         | 84.44 (70.54–93.51) |
| Residents in DENV-endemic countries | | |            |                   |
| Sri Lanka              |             |                                    |            |                   |
| DENV-1                 | 23          | 16 (69.57)                          | 16         | 69.57 (47.08–86.79) |
| DENV-2                 | 14          | 13 (92.86)                          | 13         | 92.86 (66.13–99.82) |
| DENV-4                 | 6           | 6 (100.00)                          | 6          | 100.00 (64.07–100.00) |
| All serotypes          | 43          | 35 (81.40)                          | 35         | 81.40 (66.60–91.81) |
| Vietnam                |             |                                    |            |                   |
| DENV-1                 | 20          | 19 (95.00)                          | 19         | 95.00 (75.13–99.87) |
| DENV-2                 | 4           | 4 (100.00)                          | 4          | 100.00 (39.76–100.00) |
| All serotypes          | 24          | 23 (95.83)                          | 23         | 95.83 (78.88–99.89) |
| Venezuela              |             |                                    |            |                   |
| DENV-4                 | 5           | 4 (80.00)                           | 4          | 80.00 (23.36–99.49) |
| Brazil                 |             |                                    |            |                   |
| DENV-4                 | 2           | 2 (100.00)                          | 2          | 100.00 (15.81–100.00) |
| Total                  |             |                                    |            |                   |
| DENV-1                 | 43          | 35 (81.40)                          | 35         | 81.40 (66.60–91.61) |
| DENV-2                 | 18          | 17 (94.44)                          | 17         | 94.44 (72.71–99.86) |
| DENV-4                 | 13          | 12 (92.31)                          | 12         | 92.31 (76.55–99.81) |
| All serotypes          | 74          | 64 (86.49)                          | 64         | 86.49 (76.55–93.32) |
| Total, all serotypes   | 119         | 105 (88.24)                         | 102        | 85.71 (77.12–91.45) |

*DENV, dengue virus.
†Determined by PCR.
‡Determined by correspondence with PCR results.
with samples from Vietnam, 15% fewer samples from Sri Lanka had a dominant serotype (Table 1). Serum samples from patients in Sri Lanka cross-reacted only between serotypes 1 and 2 (Appendix Figure 2); however, these samples were collected at a time when the dominant serotype in circulation was switching from DENV-1 to DENV-2 after a DENV-1 outbreak in early 2016 (W. Kumbukgolla, unpub. data). Therefore, this result could be explained by preexisting IgM or, alternatively, by co-infections. However, co-infections were not evident by PCR.

Overall, for 97.1% (102/105) of samples with a dominant serotype, ELISA results corresponded with PCR results; for patients residing in endemic regions, 100% (64/64) of the sample results corresponded, and for returning travelers, 92.7% (38/41) of the sample results corresponded (Table 1). When including the samples for which no dominant serotype was detectable, the overall serotype specificity of the Equad-based ELISA was 85.7% (Table 1); specificity of the ELISA for serum samples from persons in endemic countries was 86.5% and for returning travelers 84.4%. Because of the lower number of dominant serotypes detected, the cohort from Sri Lanka displayed a lower ELISA specificity (81.4%) than did the cohort from Vietnam (95.8%). The serotype results for the PCR-negative group from Vietnam were consistent with the PCR-positive group from Vietnam: ≈80% DENV-1 and ≈20% DENV-2 (Tables 1, 2).

Analysis of paired serum samples suggests that the results of this Equad-based ELISA are consistent over time and with different initial antibody concentrations (Figure 2). The IgM serotype initially identified as the dominant serotype remained the dominant serotype for at least 8 days (and potentially longer) after symptom onset for both returning travelers and patients residing in DENV-endemic countries, many of whom probably had secondary DENV infections (Appendix Figure 3).

**Conclusions**

Early identification of the infecting DENV serotype can be a critical component of dengue diagnosis that is also essential to pathologic and epidemiologic monitoring of outbreaks. Because of its long persistence in serum, IgM is a preferred diagnostic marker, especially when viral nucleic acids and NS1 are no longer detectable. However, serologic

Table 2. Dominant serotype determined by DENV serotype–specific IgM ELISA among DENV PCR–negative cohort (n = 14), Vietnam, 2013–2018*

| No. (%) samples with dominant serotype | DENV serotype | No. (%) samples |
|----------------------------------------|---------------|----------------|
| 13 (92.86)                             | 1             | 10/14 (71.43)  |
| 2                                      | 2             | 3/14 (21.43)   |

*DENV, dengue virus.
determination of the infecting serotype is challenging. Detection of neutralizing antibodies remains the standard method for DENV identification, but interpretation is complicated by the antigenic sin phenomenon in secondary infections (11). The possibility of using IgM to determine the infecting serotype was attempted previously (12–14), but results were complicated by low specificities, especially for secondary DENV infections. In this study, we analyzed the serotype-specific IgM responses to DENV infections in returning travelers and residents in DENV-endemic regions using recombinant mutated envelope proteins with reduced cross-reactivity (9,10). The ELISA was able to specifically detect the infecting DENV serotype in 84.4% of travelers and 86.5% of residents in DENV-endemic regions. If a dominant serotype was detected, it corresponded to the PCR result in 100% of cases in DENV-endemic regions. The finding that some sample sets did not have a dominant IgM serotype remains to be explained. Factors such as a change in the DENV serotype during an outbreak (as seen in the Sri Lanka cohort) or differing patient exposure histories could be involved. The study included DENV-3–positive serum samples from returning travelers but not from persons residing in endemic regions. However, results obtained for the other serotypes indicate that specificities were similar for samples from returning travelers and inhabitants of endemic areas.

In summary, our results suggest that specific IgM serotyping can be achieved with an ELISA-based format when using as antigens DENV envelope proteins reduced in cross-reactivity. The test can be optimized further by, for example, varying the serum dilutions tested. By using IgM-based serologic tests, which have broad diagnostic windows (15), we can more accurately report epidemiologic outbreak findings.

Parts of this work were supported by the European Union (European Funds for Regional Development grant 100216415). S.U. and A.R. are on a patent application that includes the proteins described in this study. This does not alter their adherence to policies on sharing data and materials.

About the Author
Dr. Rockstroh is a scientist at the Department of Immunology at the Fraunhofer-Institute for Cell Therapy and Immunology in Leipzig, Germany. Her research interest focus is on the serologic diagnosis of flavivirus infections.

References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. http://dx.doi.org/10.1038/nature12060
2. Gubler D, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology, vol. 1, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1153–252.
3. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929–32. http://dx.doi.org/10.1126/science.aan6836
4. Bosch I, de Puig H, Hiley M, Carré-Camps M, Perdomo-Celis F, Narváez CF, et al. Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. Sci Transl Med. 2017;9:eaa51589. http://dx.doi.org/10.1126/scitranslmed.aan1589
5. Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, Dung NM, et al. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viremia and antibody responses. PLoS Negl Trop Dis. 2009;3:e360.
6. Koraka P, Zeller H, Niedrig M, Osterhaus ADME, Groen J. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect. 2002;4:1209–15. http://dx.doi.org/10.1016/S1286-4579(02)01647-7
7. Grill WD, Chang G-JJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78:13975–86. http://dx.doi.org/10.1128/JVI.78.24.13975-13986.2004
8. Chabierski S, Barzon L, Papa A, Niedrig M, Bramson JL, Richner JM, et al. Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion loop. BMC Infect Dis. 2014;14:246. http://dx.doi.org/10.1186/1471-2334-14-246
9. Rockstroh A, Barzon L, Pacenti M, Palù G, Niedrig M, Ulbert S. Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLoS Negl Trop Dis. 2015;9:e0004218. http://dx.doi.org/10.1371/journal.pntd.0004218
10. Rockstroh A, Moses B, Barzon L, Sinigaglia A, Palù G, Kumbukgolla W, et al. Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop. Emerg Microbes Infect. 2017;6:e99. http://dx.doi.org/10.1038/s41396-017-0054-y
11. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, et al. An in-depth analysis of original antigenic sin in dengue virus infection [erratum in J Virol. 2011;85:12100]. J Virol. 2011;85:410–21. http://dx.doi.org/10.1128/JVI.01826-10
12. Nawa M, Yamada KI, Takasaki T, Akatsuka T, Kurane I. Serotype-cross-reactive immunoglobulin M responses in dengue virus infections determined by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2000;7:774–7.
13. Shu P-Y, Chen L-K, Chang S-F, Su C-L, Chien L-J, Chin C, et al. Dengue virus serotyping based on envelope and membrane and nonstructural protein NS1 serotype-specific capture immunoglobulin M enzyme-linked immunosorbent assays. J Clin Microbiol. 2004;42:2489–94. http://dx.doi.org/10.1128/JCM.42.6.2489-2494.2004
14. Zidane N, Dussart P, Bedouelle H. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the flavivirus envelope glycoprotein cross-reactive epitopes. JVI.01826-10
15. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. PLoS Negl Trop Dis. 2014;8:e3171. http://dx.doi.org/10.1371/journal.pntd.0003171

Address for correspondence: Sebastian Ulbert, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, Leipzig 04103, Germany; email: sebastian.ulbert@izi.fraunhofer.de

Dengue Virus IgM Serotyping with Envelope Proteins
Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins

Technical Appendix

Recombinant Proteins

Dengue virus (DENV) envelope proteins with 4 point mutations resulting in 4 amino acid changes in and near the conserved fusion loop (T76R, Q77E, W101R, L107R; referred to as Equad proteins) were generated by using the Drosophila Schneider S2-cell expression system (ThermoFisher Scientific, https://www.thermofisher.com/us/en/home.html). We inserted into the pMT/BiP/V5-His vector (Invitrogen, https://www.thermofisher.com/us/en/home.html) nucleotides corresponding to the following envelope amino acid sequences: 1–399 of DENV-1 strain Nauru/West Pac/1974, 1–399 of DENV-2 strain 16681, 1–397 of DENV-3 strain Sri Lanka/1266/2000, and 1–399 of DENV-4 strain Dominica/814669/1981. Purifications from the S2-cell culture supernatant were carried out via nickel-affinity and subsequent size-exclusion chromatography, as described (1).

ELISA

The IgM ELISA was carried out as described previously (1) but with modifications needed to acquire single-antigen measurements using serum dilutions. In brief, the Equad protein of each DENV serotype (300 ng/well) was coated separately overnight on Nunc Maxisorb plates (Invitrogen) in 100 µL coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, pH 9.6) at 4°C. The plates were washed 3 times with 350 µL/well of phosphate-buffered saline with tween (0.05%) and blocked with 200 µL of 5% nonfat milk powder (blocking solution) for 2 h at room temperature. After washing, human serum samples were serially 2-fold diluted from 1:100 to 1:12,800 in blocking solution and 100 µL/well were added and incubated at room temperature for 1.5 h. After another washing step, the horseradish peroxidase–conjugated secondary rabbit anti–human µ-chain IgM antibody (Dianova, https://www.dianova.com/en/) was diluted 1:7,500.
in blocking solution and 100 µL/well were added for 1 h at room temperature. After washing, 100 µL/well of TMB substrate (Biozol, https://www.biozol.de/en/) were added and incubated at room temperature for 30 min. The reaction was stopped with 50 µL 1 M H₂SO₄ and signals were read at 450 nm with background reduction at 520 nm in a micro plate reader (Infinite M200; Tecan, https://www.tecan.com/). All tests were performed in duplicates and in 2 independent experiments.

**Appendix Table.** Positivity cutoffs for the determination of endpoint titers for DENV serotype–specific IgM ELISA*

| Equad protein | Cutoff† |
|---------------|---------|
| DENV-1        | 0.2766  |
| DENV-2        | 0.2410  |
| DENV-3        | 0.2186  |
| DENV-4        | 0.2193  |

*DENV, dengue virus; Equad, envelope protein with 4 amino acid changes.
†Cutoffs were calculated by taking the value of the mean plus 2× the SD of 15 negative control serum samples.
Appendix Figure 1. IgM endpoint titers of DENV-1–4 PCR–positive serum samples from returning travelers, 2013–2016, on DENV 1–4 Equad proteins. Equad proteins are the envelope proteins from DENV with 4 amino acid changes (T76R, Q77E, W101R, and L107R). DENV, dengue virus.
Appendix Figure 2. IgM endpoint titers of DENV-1, DENV-2, and DENV-4 PCR–positive and NS1 antigen–positive serum samples from residents of dengue endemic countries Vietnam, Sri Lanka, Venezuela, and Brazil, 2013–2018, on DENV 1–4 Equad proteins. Equad proteins are the envelope proteins from DENV with 4 amino acid changes (T76R, Q77E, W101R, and L107R). DENV, dengue virus.
Appendix Figure 3. IgM/IgG ratios for serum samples obtained from patients in the DENV endemic countries of Vietnam (n = 38), Sri Lanka (n = 43), Venezuela (n = 5), and Brazil (n = 2), 2013–2018. The DENV-IgG ELISA was performed as previously described (1). The dotted line represents a cutoff for the discrimination of probable primary and secondary infections in which samples with values placed above the line represent primary infections (2,3).

References

1. Rockstroh A, Barzon L, Pacenti M, Palù G, Niedrig M, Ulbert S. Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLoS Negl Trop Dis. 2015;9:e0004218. PubMed http://dx.doi.org/10.1371/journal.pntd.0004218

2. Domingo C, de Ory F, Sanz JC, Reyes N, Gascón J, Wichmann O, et al. Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagn Microbiol Infect Dis. 2009;65:42–8. PubMed http://dx.doi.org/10.1016/j.diagmicrobio.2009.05.004

3. Carrasco CD. ECDC training workshop on laboratory diagnosis of dengue virus infections, Berlin, 23-27 January 2012. Diagnostics algorithms in dengue infections. 2012 [cited 2018 Apr 7]. http://enivd.de/ECDC/pdf/dc_ml_24_cd_v.pdf